UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16 of
the Securities Exchange Act of 1934
Date of Report: November
2, 2015
Commission File Number: 001-36891
Cellectis S.A.
(Exact
Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33
1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ⃞
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞
EXHIBIT INDEX
|
Exhibit |
Title |
|
|
99.1 |
Press release, dated November 2, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CELLECTIS S.A. |
|||
|
(Registrant) |
|||
|
November 2, 2015 |
By: |
/s/ André Choulika |
|
|
André Choulika |
|||
|
Chief Executive Officer |
|||
3
Exhibit 99.1
Calyxt Completes the First Field Trials of Its Cold Storable Potato Product
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--November 2, 2015--Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products to benefit both consumers and farmers, today announced that it has completed the first field trials in Minnesota, Wisconsin and Michigan of its cold storable potato.
A significant amount of potatoes harvested each fall are cold-stored to ensure a continuous supply throughout the year. During cold storage, reducing sugars can accumulate in the potatoes and when cooked at temperatures above 250°F, the reducing sugars interact with free amino acids to form acrylamide. The National Toxicology Program and the International Agency for Research on Cancer considers acrylamide a ‘probable’ human carcinogen.
Our scientists at Calyxt have inactivated the enzyme responsible for the degradation of sugars in the tuber, thus reducing both the sweetening of cold-stored potatoes and also the creation of acrylamide during frying.
Calyxt has previously validated the effectiveness of its cold-storable potatoes in the greenhouse and the harvest of the multi-location field trials is an important next step for demonstrating the cold-storable trait from field-grown material. In addition to increasing the amount of material to conduct commercial cold storage assays, certified seed production is underway to facilitate a commercial launch.
“We are very pleased by the results of our field trials, that continues to demonstrate Calyxt is an innovated player in the potato industry. Cold-storable, non-transgenic potatoes provide a continuous, high quality supply of potatoes and also increases the usable yield for the French fries, potato chips and fresh market industries,” said Dan Voytas, Chief Scientific Officer of Calyxt, Inc.
About Calyxt
Founded in 2010, Calyxt, Inc. (previously Cellectis plant sciences,
Inc.) is based in New Brighton, Minnesota (USA). The company aims to
create healthier crop products such as low trans fat soybean oil,
cold-storable potato, gluten reduced wheat and low saturated fat canola
oil for the food and agriculture industries. Calyxt is developing a
network of partnerships in order to secure accessibility of its food
products to consumers.
For further information please visit our
website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis SA in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
CONTACT:
For further information, please contact:
Media
contacts
Jennifer Moore, VP Communications
Phone: 917-580-1088
email:
media@cellectis.com
or
Caitlin Kasunich / Dixon Moretz
KCSA
Strategic Communications
212.896.1241 / 212.896.1251
ckasunich@kcsa.com
/ dmoretz@kcsa.com
or
Investor Relations contact
Simon
Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email:
simon.harnest@cellectis.com